Gamma Or Immune Patents (Class 424/85.5)
-
Publication number: 20100135955Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: November 12, 2009Publication date: June 3, 2010Applicant: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Publication number: 20100135957Abstract: Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.Type: ApplicationFiled: December 16, 2009Publication date: June 3, 2010Inventors: Vincent Danial Fitzpatrick, Mark Sliwkowski, Richard L. Vandlen
-
Publication number: 20100135960Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.Type: ApplicationFiled: November 17, 2009Publication date: June 3, 2010Inventors: Yat Sun Or, Lu Ying, Ce Wang, Xiaowen Peng, Yao-Ling Qiu
-
Patent number: 7727520Abstract: The present invention provides compositions and methods for promoting the healing of wounds or fibrotic disorders with reduced scarring, comprising inhibitors and inhibiting IFN-?, together with compositions and methods for promoting the healing of chronic wounds, comprising stimulating and stimulators of IFN-?.Type: GrantFiled: July 5, 2007Date of Patent: June 1, 2010Assignee: Renovo LimitedInventor: Mark William James Ferguson
-
Publication number: 20100129428Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising interferon associated with a lipid construct comprising amphipathic lipid molecules and receptor binding molecule. The composition can comprise a mixture of free interferon and interferon associated with the complex. The composition can be modified to protect interferon and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading interferon into the composition and recycling various components of the composition and methods of treating individuals infected with the hepatitis C and other hepatitis viruses.Type: ApplicationFiled: May 16, 2006Publication date: May 27, 2010Inventors: John R. Lau, W. Blair Geho
-
Publication number: 20100124544Abstract: The present invention relates to the crystalline forms of 2-allyl-1-[6-(I-hydroxy-1 methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one or a salt thereof, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.Type: ApplicationFiled: April 22, 2008Publication date: May 20, 2010Inventors: Masashi Kawasaki, Hiroo Mizuno, Toshihiro Sakamoto, Kimimasa Suzuki, Arlene E. Mckeown
-
Publication number: 20100119479Abstract: Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.Type: ApplicationFiled: October 14, 2009Publication date: May 13, 2010Applicant: INTERMUNE, INC.Inventors: BRAD BUCKMAN, VLADIMIR SEREBRYANY, SCOTT SEIWERT, LEONID BEIGELMAN, ANTITSA STOYCHEVA
-
Publication number: 20100119474Abstract: The invention provides a method of determining the likelihood that a smoker will or will not develop chronic obstructive pulmonary disease (COPD) by obtaining a sample from the smoker, analyzing the sample for the expression of a set of biomarkers associated with COPD, and comparing the expression pattern determined in the sample with a standard expression pattern to determine the likelihood that the smoker will or will not develop COPD. The invention further provides a composition, a method of treatment, and methods of determining the efficacy of treatment for COPD.Type: ApplicationFiled: March 6, 2008Publication date: May 13, 2010Applicant: Cornell UniversityInventors: Ronald G. Crystal, Neil R. Hackett, Adriana Heguy, Ben-Gary Harvey, Philip L. Leopold, Ann E. Tilley, Timothy O'Connor
-
Publication number: 20100119477Abstract: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.Type: ApplicationFiled: December 4, 2009Publication date: May 13, 2010Inventors: Michael Otto, Rong Wang
-
Publication number: 20100119446Abstract: The present invention relates to a recombinant binding protein comprising at least one derivative of the Src homology 3 domain (SH3) of the FYN kinase, wherein at least one amino acid in or positioned up to two amino acids adjacent to the src loop and/or at least one amino acid in or positioned up to two amino acids adjacent to the RT loop is substituted, deleted or added. Furthermore, the invention is directed to fusion proteins comprising a binding protein according to the invention fused to a pharmaceutically and/or diagnostically active component. In addition, the invention concerns nucleotides coding for these binding and/or fusion proteins as well as corresponding vectors and host cells. Last but not least, the present invention relates to the use of binding and/or fusion proteins of the present invention for preparing a medicament or a diagnostic means as well as to pharmaceutical or diagnostic compositions comprising said binding and/or fusion proteins.Type: ApplicationFiled: August 20, 2007Publication date: May 13, 2010Applicant: EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICHInventors: Dragan Grabulovski, Dario Neri
-
Publication number: 20100112070Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: December 29, 2009Publication date: May 6, 2010Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20100111902Abstract: The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Applicant: CEPHALON, INC.Inventors: Steve L. Durfee, Gary Thurman
-
Publication number: 20100098630Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.Type: ApplicationFiled: December 28, 2007Publication date: April 22, 2010Applicant: AMBRX, INC.Inventor: Zhenwei Miao
-
Publication number: 20100098660Abstract: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon ?, interferon ? or interferon ? in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.Type: ApplicationFiled: October 20, 2009Publication date: April 22, 2010Inventors: Rany CONDOS, Gerald SMALDONE
-
Publication number: 20100086517Abstract: Compositions and methods for modulating the growth, proliferation, and/or differentiation of B-cells in the germinal center are disclosed, and include use of IL-15 inhibitors, antagonists, and agonists. The compositions and methods find use in treating B-cell-related disorders, including neoplasms of the B-cell lineage.Type: ApplicationFiled: June 15, 2009Publication date: April 8, 2010Applicant: Ochsner Clinic FoundationInventor: Yong Sung Choi
-
Publication number: 20100074863Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.Type: ApplicationFiled: September 17, 2009Publication date: March 25, 2010Inventors: Yat Sun Or, Ce Wang, Xiaowen Peng, Lu Ying, Yao-Ling Qiu
-
Publication number: 20100068177Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.Type: ApplicationFiled: August 28, 2009Publication date: March 18, 2010Applicant: The General Hospital CorporationInventor: Denise L. Faustman
-
Publication number: 20100068174Abstract: Disclosed herein are methods of treating an immunosensitive cancer with bis(thio-hydrazide amides) or pharmaceutically-acceptable salts thereof and an immunotherapy.Type: ApplicationFiled: August 20, 2007Publication date: March 18, 2010Inventor: Eric Jacobson
-
Publication number: 20100055072Abstract: The present invention relates to new 2-oxo-1,2-dihydro-quinoline modulators of immune function, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: September 2, 2009Publication date: March 4, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Manoucher M. Shahbaz
-
Publication number: 20100047205Abstract: The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at (east one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-? (gamma) and TNF-? (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.Type: ApplicationFiled: July 24, 2007Publication date: February 25, 2010Inventors: John W. Hadden, Kathy Signorelli, James Egan
-
Publication number: 20100040576Abstract: The invention relates to compositions and methods related to the treatment of viral infection. In some embodiments, the invention relates to the treatment of hepatitis C viral infection. In further embodiments, the invention relates to methods of administering oligonucleotide compositions for treating viral infections. In still further embodiments, the invention relates to the administration of antiviral agents, corticosteroids and immunomodulatory agents. In additional embodiments, the invention relates to the manipulation of immunostimulatory motifs within the oligonucleotides.Type: ApplicationFiled: December 16, 2008Publication date: February 18, 2010Inventors: Chia-Cheng Kao, Kumar Ranjith Tharachaparamba
-
Publication number: 20100034738Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.Type: ApplicationFiled: July 21, 2009Publication date: February 11, 2010Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
-
Publication number: 20100028451Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: September 26, 2007Publication date: February 4, 2010Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Xiaoqin Wang
-
Publication number: 20100021427Abstract: The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.Type: ApplicationFiled: May 29, 2009Publication date: January 28, 2010Applicant: Tianjin FusoGen Pharmaceuticals, Inc.Inventors: Xin Chen, Linqi Zhang, Shibo Jiang
-
Publication number: 20100003217Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: July 1, 2009Publication date: January 7, 2010Inventors: Erika Cretton-Scott, Brenda Hernandez-Santiago, Marita Larsson, Kusum Gupta
-
Publication number: 20090324544Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.Type: ApplicationFiled: June 11, 2009Publication date: December 31, 2009Inventors: Yao-Ling Qiu, Ce Wang, Jiang Long, Lu Ying, Yat Sun Or
-
Publication number: 20090304776Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.Type: ApplicationFiled: December 19, 2008Publication date: December 10, 2009Inventors: Totada Shantha, Jessica Shantha, Erica Shantha, Lauren Shantha
-
Publication number: 20090304628Abstract: The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.Type: ApplicationFiled: October 27, 2006Publication date: December 10, 2009Inventors: Iraldo Bello Rivero, Pedro López Saura, Yanelda Garcia Vega, Héctor Santana Milian, Ana Aguilera Barreto, Rolando Pâez Meireles, Lorenzo Anasagasti Angulo
-
Publication number: 20090304580Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Lea and Le(y) antibodies that bind to the Lewis antigens.Type: ApplicationFiled: August 7, 2009Publication date: December 10, 2009Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang, David V. Gold
-
Publication number: 20090297476Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: May 9, 2008Publication date: December 3, 2009Applicants: InterMune, Inc., Array Biopharma Inc.Inventors: SCOTT SEIWERT, STEVEN W. ANDREWS, LEONID BEIGELMAN, LAWRENCE M. BLATT, BRAD BUCKMAN, Kevin R. Condroski, Yutong Jiang, Robert J. Kaus, April L. Kennedy, Timonthy S. Kercher, Michael A. Lyon, Bin Wang
-
Publication number: 20090297471Abstract: Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×109 NK cells per kilogram weight of the subject from which the cells are harvested.Type: ApplicationFiled: May 26, 2005Publication date: December 3, 2009Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Luis F. Porrata
-
Publication number: 20090297475Abstract: The invention relates to the detection and identification of polymorphisms in cysteine dioxygenase (CDO) for the use of that diagnosis to identify a propensity in a patient towards rheumatoid arthritis and/or to have side effects with a number of drugs, to nucleic acid and isolated proteins encoding the polymorphisms, to assays for CDO activity and for the identification of compounds affecting CDO activity, and additionally to use of interferon-? optionally in combination with different compounds, to treat rheumatoid arthritis.Type: ApplicationFiled: July 20, 2006Publication date: December 3, 2009Applicant: THE UNIVERSITY OF BIRMINGHAMInventors: Rosemary Hope Waring, David Boyer Ramsden, Lucy Jane Wilkinson, Hugh Kikuchi
-
Publication number: 20090297573Abstract: The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in at least a portion of the nervous system of an individual subjected to conditions known to result in altered nervous system plasticity, i.e., dark rearing (DR) or monocular deprivation (MD). The genes are targets for pharmacological agents that modify plasticity. The invention also identifies biological pathways that are enriched in genes that are differentially regulated under conditions known to result in altered nervous system plasticity. The present invention further provides methods and compositions for modifying plasticity in the nervous system of a subject.Type: ApplicationFiled: April 12, 2007Publication date: December 3, 2009Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Mriganka Sur, Daniela Tropea, Gabriel Kreiman
-
Publication number: 20090291062Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.Type: ApplicationFiled: November 28, 2008Publication date: November 26, 2009Inventors: Wolfgang FRAUNHOFER, Annika Bartl, Hans-juergen Krause, Markus Tschoepe, Katharina Kaleta
-
Publication number: 20090291049Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 22, 2008Publication date: November 26, 2009Applicants: Universidade De Coimbra, Centro De Neurociencias E Biologia CelularInventors: Joao Nuno Sereno de Almeida Moreira, Vera Lucia Dantas Nunes Caldeira de Moura, Sergio Paulo de Magalhaes Simoes, Maria da Conceicao Monteiro Pedroso de Lima
-
Publication number: 20090291144Abstract: The invention discloses therapeutic and prophylactic compositions based on synthetic solid catalysts such as zeolites, clays, silicates, silicas and double hydroxides. These solids can be used to treat numerous disease conditions such as diabetes, arthritis and other autoimmune diseases, cancer, skin diseases, microbial infections etc. The invention also describes methods to produce such products and use them independently or in combination with other pharmaceutically and biologically active ingredients. Such catalysts are designed so to imitate biological catalytic systems (enzymes, antigen presenting cells, delayed active component release, cell organeles, etc.) and are, therefore, biomimetic.Type: ApplicationFiled: August 3, 2009Publication date: November 26, 2009Inventor: Miroslav Colic
-
Patent number: 7622105Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.Type: GrantFiled: January 25, 2006Date of Patent: November 24, 2009Assignee: Fondazione Centro San Raffaele Del Monte TaborInventor: Angelo Corti
-
Publication number: 20090285771Abstract: Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a macromolecule to be delivered to a subject, and a cleavable linker. Generally, the cleavable linker is cleavable by an enzyme present in higher concentration at or near the basal-lateral membrane of a polarized epithelial cell or in the plasma than elsewhere in the body, for example, at the apical side of the polarized epithelial cell. In other aspects, the invention provides nucleic acids encoding delivery constructs of the invention, kits comprising delivery constructs of the invention, cells expressing delivery constructs of the invention, and methods of using delivery constructs of the invention.Type: ApplicationFiled: October 4, 2005Publication date: November 19, 2009Applicant: Trinity Biosystems, Inc.Inventor: Randall J. Mrsny
-
Publication number: 20090285752Abstract: The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.Type: ApplicationFiled: May 18, 2009Publication date: November 19, 2009Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans J. HANSEN
-
Publication number: 20090280164Abstract: A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.Type: ApplicationFiled: June 5, 2008Publication date: November 12, 2009Inventor: Teni BOULIKAS
-
Publication number: 20090274656Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: September 2, 2008Publication date: November 5, 2009Inventors: Alan Xiangdong Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
-
Publication number: 20090269305Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: April 14, 2009Publication date: October 29, 2009Applicant: InterMune, Inc.Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
-
Publication number: 20090269303Abstract: This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to the individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor being capable of inducing endothelial CD73 expression, or a combination thereof. In addition, the invention concerns a method for prevention or treatment of a disease or disorder requiring or benefiting from the elevation of the adenosine level in an individual. Furthermore, the invention concerns a method of up-regulating endothelial CD73 expression in an individual by administering to the individual an effective amount of a cytokine or another factor being capable of inducing endothelial CD73 expression, and to a method for prevention or treatment of a disease or disorder requiring or benefiting from up-regulating endothelial CD73 expression.Type: ApplicationFiled: April 24, 2009Publication date: October 29, 2009Applicant: FARON PHARMACEUTICALS OYInventor: Sirpa JALKANEN
-
Publication number: 20090263354Abstract: The invention relates to C/EBP? and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBP? thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy.Type: ApplicationFiled: March 10, 2009Publication date: October 22, 2009Applicant: Yeda Research and Development Co., Ltd.Inventors: Menachem Rubinstein, Ofir Meir
-
Publication number: 20090257979Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: April 14, 2009Publication date: October 15, 2009Applicant: INTERMUNE, INC.Inventors: Leonid Beigelman, Guangyi Wang, Brad O. Buckman, Antitsa Dimitrova Stoycheva
-
Publication number: 20090257980Abstract: The present invention provides the use of IFN-?, an agent that increases the expression of IFN-?, or a polynucleotide which is capable of expressing IFN-? or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-? for the same purpose.Type: ApplicationFiled: June 18, 2009Publication date: October 15, 2009Inventors: Donna Elizabeth DAVIES, Peter Alexander Blanch Wark, Stephen Holgate, Sebastian L. Johnston
-
Patent number: 7597884Abstract: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same.Type: GrantFiled: February 8, 2006Date of Patent: October 6, 2009Assignee: Alios BioPharma, Inc.Inventors: Lawrence M. Blatt, Scott D. Seiwert, Jin Hong
-
Publication number: 20090246174Abstract: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.Type: ApplicationFiled: December 28, 2006Publication date: October 1, 2009Inventors: Alain H. Rook, Bernice M. Benoit, Maria Wysocka, Sarah M. Bray, Richard L. Miller, Mark A. Tomai
-
Publication number: 20090238789Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.Type: ApplicationFiled: November 28, 2007Publication date: September 24, 2009Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
-
Publication number: 20090238793Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.Type: ApplicationFiled: May 15, 2007Publication date: September 24, 2009Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventor: Jayakrishina Ambati